Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 275 posts found.

janssen_latest_logo_on_sign

FDA expands Stelara indication to cover paediatric plaque psoriasis

July 31, 2020
Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis

Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …

News
china-pharmaceutical-industry

Emergent forges five-year partnership to produce one billion doses of Janssen’s COVID-19 vaccine

July 7, 2020
Manufacturing and Production COVID-19, Emergent, J&J, JJ, Janssen, coronavirus

As many pharma firms move to secure upscaled manufacturing capacity for their potential COVID-19 vaccines, Johnson & Johnson’s Janssen has …

News
janssen_latest_logo_on_sign_closer

Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says

June 15, 2020
Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis

Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …

News
janssen_latest_logo_on_sign_closer

Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies

June 4, 2020
Research and Development Janssen, Tremfya, psoriatic arthritis

Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …

News
janssen_latest_logo_on_sign_closer

100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows

May 14, 2020
Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …

News
janssen_latest_logo_on_sign_closer

NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020
Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …

News
nhs_sign_8

Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

April 15, 2020
Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …

News
36745826313_86e4ffa6ac_b

New Johnson & Johnson study aiming to add stroke detection to Apple Watch

February 26, 2020
Research and Development Apple, Janssen, Johnson & Johnson, apple watch, iphone, stroke

Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection. It …

News
janssen_latest_logo_on_sign_closer

Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease

February 18, 2020
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …

News
janssen_latest_logo_on_sign_closer

Janssen’s Erleada expanded in Europe to cover metastatic hormone-sensitive prostate cancer

January 29, 2020
Research and Development, Sales and Marketing Erleada, Europe, Janssen, pharma

Janssen’s Erleada (apalutamide) has secured expanded authorisation from the European Commission (EC), approving its label to include the treatment of …

News
janssen_latest_logo_on_sign

NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression

January 28, 2020
Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression

Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …

News
janssen_latest_logo_on_sign_closer

European Commission expands Stelara for paediatric moderate to severe plaque psoriasis

January 24, 2020
Research and Development Europe, Janssen, Stelara, pharma

Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis …

News
janssen_latest_logo_on_sign

European Commission authorises Janssen’s anti-depressant Spravato

December 23, 2019
Sales and Marketing Janssen, MDD, Nasal Spray, TRD, depression, mental health

The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that …

News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …

News
johnson_and_johnson_jj_4

J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak

November 7, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma

Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024